General
Preferred name
EMTRICITABINE
Synonyms
BW1592 ()
Emtriva ()
FTC ()
(-)-Emtricitabine ()
EMTRICITABINE, (+/-)- ()
Genvoya-emtricitabine ()
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one ()
Emtricitabine (BW 1592) ()
FTC, BW1592 ()
Biktarvy ()
(-)-FTC ()
Emtricitabine, (-)- ()
FTC-(-) ()
524W91 ()
BW-524W91 ()
524-W-91 ()
Emtricitabinum ()
Coviracil ()
P&D ID
PD009667
CAS
143491-57-0
143491-54-7
Tags
prodrug
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
2003
Drug Status
investigational
approved
Drug indication
Hepatitis B virus infection
Human immunodeficiency virus infection
Hepatitis virus infection
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA
Emtricitabine works by inhibiting reverse transcriptasem preventing transcription of HIV RNA to DNA. Emtricitabine is a synthetic nucleoside analogue of cytidine. It is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which is responsible for the inhibition of HIV-1 reverse transcriptase. It competes with the natural substrate deoxycytidine 5'-triphosphate and incorporates into nascent viral DNA, resulting in early chain termination. Therefore emtricitabine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate deoxycytidine 5'-triphosphate and by its incorporation into viral DNA. By inhibiting HIV-1 reverse transcriptase, emtricitabine can help to lower the amount of HIV, or "viral load", in a patient's body and can indirectly increase the number of immune system cells (called T cells or CD4+ T-cells).
DESCRIPTION
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral compound.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
4
Compound Sets
22
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
50
Molecular Weight
247.04
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-0.46
TPSA
90.37
Fraction CSP3
0.5
Chiral centers
2.0
Largest ring
6.0
QED
0.73
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Metabolic Enzyme/Protease
Target
Reverse Transcriptase
NRT inhibitor
Endogenous Metabolite
HIV
HBV,HIV,Reverse Transcriptase
Indication
human immunodeficiency virus (HIV-1)
MOA
nucleoside reverse transcriptase inhibitor
Biosynthetic Origin
Nucleoside
Therapeutic Indication
Antiviral
Therapeutic Class
Anti-HIV Agents
Source data
